Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab

The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal cancer treatment, but many patients treated with cetuximab don't respond o...

Full description

Saved in:
Bibliographic Details
Main Authors: Iida, Mari, Brand, Toni M, Starr, Megan M, Li, Chunrong, Huppert, Evan J, Luthar, Neha, Pedersen, Mikkel W, Horak, Ivan D, Kragh, Michael, Wheeler, Deric L
Format: Artigo
Language:Inglês
Published: Neoplasia Press Inc. 2013
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3819635/
https://ncbi.nlm.nih.gov/pubmed/24204198
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items